The most important object at Neurocrine Biosciences is small enough to swallow. INGREZZA, known to chemists as valbenazine, is a capsule designed to quiet involuntary movements by inhibiting VMAT2, a protein involved in packaging neurotransmitters such as dopamine. For patients with tardive dyskinesia - repetitive movements that can follow long exposure to certain psychiatric medicines - that mechanism can make everyday gestures less unruly. For Neurocrine, it did something else: it converted decades of patient research into a durable commercial business.
INGREZZA generated $2.51 billion in net product sales in 2025, almost 88 percent of Neurocrine's total revenue that year. This is the sort of success every biotech wants and every management team learns to fear. One medicine supplies the money, the identity and the concentration risk. The company now has to use that advantage without becoming trapped by it.
A name that explains the thesis
“Neurocrine” compresses neurological and endocrine into one word. It is a useful clue. The company was founded in San Diego in 1992 by Wylie Vale, an endocrinologist at the Salk Institute, and Lawrence Steinman, a neurologist at Stanford. Vale's work helped identify corticotropin-releasing factor, or CRF, a hormone that coordinates the body's stress response. The founding idea was less a single technology than a territory: the chemical conversation between brain, pituitary gland, hormones and behavior.
That territory is still visible in the portfolio. INGREZZA is used in movement disorders. CRENESSITY, approved in 2024, blocks the CRF1 receptor and is used alongside glucocorticoids for classic congenital adrenal hyperplasia, or CAH. VYKAT XR, acquired with Soleno Therapeutics in May 2026, treats hyperphagia - persistent, dangerous hunger - in people with Prader-Willi syndrome. The late-stage pipeline reaches into schizophrenia and major depressive disorder. Different clinics, different patient groups, but a recurring interest in precise biological levers that influence complex symptoms.
What patients actually receive
Neurocrine does not sell a research platform to other companies. It primarily sells prescription medicines in the United States through specialty pharmacies and distributors. Clinicians diagnose and prescribe; insurers and pharmacy benefit systems decide coverage; patients and caregivers navigate delivery, reimbursement and continued use. The customer journey is therefore less like buying a bottle and more like moving through a carefully managed relay race.
INGREZZA treats adults with tardive dyskinesia and chorea associated with Huntington's disease. It is also available in a sprinkle formulation for patients who have difficulty swallowing capsules. CRENESSITY is taken with glucocorticoids by adults and children age four and older with classic CAH, a genetic condition in which deficient cortisol production drives excess androgen. VYKAT XR is approved for the defining hyperphagia of Prader-Willi syndrome in adults and children age four and older. In each case, the problem is not merely an abnormal lab value. It is an exhausting daily burden carried by patients, families and clinicians.
That burden can be hard to see from the outside. Tardive dyskinesia may make a person blink, grimace or move the tongue without intending to; the visibility of the condition can compound the underlying psychiatric illness with embarrassment and isolation. Huntington's chorea can interfere with balance, speech and ordinary tasks. In classic CAH, patients require lifelong hormone management, while high glucocorticoid exposure brings problems of its own. Hyperphagia in Prader-Willi syndrome can compel relentless food seeking and force families to organize locks, routines and supervision around hunger. Neurocrine's market is built from these very specific frictions.
For clinicians and patients, the company's practical value is choice within categories that have had too little of it. A targeted drug does not erase the need for diagnosis, monitoring or the rest of a care plan. It can, however, give a specialist another lever and give a family a treatment designed around the symptom disrupting daily life. Neurocrine also operates access-support programs because an FDA approval is only theoretical if a prescription stalls between the doctor's office, the insurer and the specialty pharmacy.
The business also has a quieter royalty layer. Neurocrine discovered and developed elagolix through Phase 2 before licensing global rights to AbbVie in 2010. AbbVie pays for development and commercialization of ORILISSA for endometriosis and ORIAHNN for heavy menstrual bleeding associated with uterine fibroids; Neurocrine receives tiered royalties. The arrangement is a reminder that a drug developer need not commercialize every molecule itself to preserve meaningful economics.
One medicine built the balance sheet. The next portfolio has to prove it built a company.The concentration test
The expensive escape from one-product gravity
Neurocrine paid $2.9 billion in cash for Soleno, bringing VYKAT XR into the fold barely a year after its FDA approval. The logic was immediate diversification. VYKAT XR had generated $190 million for Soleno in 2025, including $92 million in the fourth quarter, and came with intellectual property expected to extend into the mid-2040s. Neurocrine brought an existing rare-disease commercial organization, patient-support experience and cash. Soleno brought a marketed medicine with a distinct patient community.
The deal also sharpened Neurocrine's market position. It is no longer best described as a movement-disorder company with a pipeline. It is becoming a specialist biopharma built around first-in-class medicines for disorders that larger pharmaceutical companies have often under-addressed. This is a narrower identity than “big pharma” and a broader one than “neuroscience biotech.” It lives in the middle: enough commercial scale to launch nationally, enough scientific focus to pursue small populations and difficult mechanisms.
That distinction matters competitively. Teva's AUSTEDO and AUSTEDO XR are direct VMAT2 alternatives in tardive dyskinesia and Huntington's chorea. Traditional glucocorticoid regimens remain central in CAH. In schizophrenia, established antipsychotics and newer approaches such as Bristol Myers Squibb's COBENFY raise the bar for any investigational muscarinic medicine. Neurocrine's differentiation is not that it lacks rivals. It is the combination of receptor-level expertise, focused field teams, reimbursement support and the willingness to work on conditions where diagnosis itself can be inconsistent.
The same focus creates vulnerabilities. Drug pricing and reimbursement can reduce the net value of each prescription. Generic entry can compress a mature franchise. Safety findings or disappointing clinical data can change a program's future in an afternoon. Neurocrine uses third parties for important parts of manufacturing and development, so execution extends beyond its own walls. And while three commercial medicines look sturdier than one, INGREZZA still carries most of the economic weight. The relevant comparison is not simply with another San Diego biotech; it is with every company competing for the same prescriber attention, payer budget, trial sites and scarce clinical-development talent.
A pipeline with more than one accent
The pipeline now spreads across four therapeutic areas: psychiatry, neurology, endocrinology and immunology. Its headline trials include direclidine, an M4-preferring muscarinic agonist in Phase 3 for schizophrenia, and osavampator, an AMPA positive allosteric modulator in Phase 3 for major depressive disorder. Earlier programs test additional M1 and M4 agonists, a next-generation VMAT2 inhibitor, sodium-channel inhibition for epilepsy, CRF-targeting peptides and approaches to obesity. Investigational therapies, of course, are questions rather than products; most drug-development questions do not receive the answer their sponsors want.
Partnerships widen the scientific aperture. Nxera Pharma contributed muscarinic programs; Takeda contributed psychiatry assets; Xenon brought sodium-channel work in epilepsy; Voyager added gene-therapy capabilities. Neurocrine can license specialist science, finance later development and retain substantial commercial rights. That model avoids the vanity of pretending every good idea must originate inside one campus.
Scale, with a human odd streak
The company has grown from two founders to more than 2,000 employees, yet its public culture language has an unexpectedly loose thread. Employees describe Neurocrine as caring, collaborative, fun, supportive and “a little bit weird.” Against the beige vocabulary of corporate values, the final phrase feels almost rebellious. The formal list is passion, integrity, collaboration, innovation and tenacity. The lived aspiration is a workplace where scientists, commercial teams and patient advocates can still sound like people.
There are practical investments behind the wording: internships, USC-linked pharmaceutical fellowships, leadership development and a new San Diego headquarters described as LEED Silver-eligible. Culture will be tested by the same thing testing the portfolio - scale. Integrating Soleno, expanding sales teams and running several late-stage programs creates more process, more handoffs and more opportunities for the research-company reflexes to get lost.
Financially, momentum is visible. Neurocrine reported $959 million in second-quarter 2026 revenue, up 39 percent from a year earlier. But revenue is not the ending of this story. It is the fuel. The consequential outcomes will arrive in clinics: whether a psychiatrist gains a genuinely different option for schizophrenia, whether children with CAH can be treated earlier, whether families living with Prader-Willi syndrome can access VYKAT XR, and whether the company can make its second act less dependent on the capsule that funded it.